RE:RE:RE:crpof is on the right trackEverything is relative, you're back in at a good time.
The Noble analyst had 2020 year rev at $13.4M, R&D at $2.7M and net income at -2.2M.
After H1, rev. is at $8.9M, R&D at .9M and net income at $2.2M.
If H2 is similar to H1, and even with R&D picking up to say $1.5M in H2, we could hit $3 - $3.8M, or conservatively .04 EPS.
This year we are given an opportunity to use earnings to give a valuation of the company. Growing revenues in the 30 to 40% range, potential .04 EPS, what PE or PEG would be applicable here? That's just a strict valuation for the base business. As you know, lots in the pipleine with PGX deal slated any month now. Is there less risk now at .80's than 8 months ago at .30's, I would say yes. As we all believe here, tremendous upside that the market has not recognized.